Health Secretary Matt Hancock publicly thanks Randox for ‘stepping up to the mark’
Health Secretary Matt Hancock publicly thanks Randox for ‘stepping up to the mark’
On 23 April 2020, UK Health Secretary Matt Hancock personally thanked staff at Randox for the work we have done and continue to do, during the daily coronavirus briefing from Downing Street.
“I want to take this moment to applaud the private companies who have been involved…Boots, Amazon, Thermo Fisher, Randox, Rosch, Oxford Nanopore, GSK and Astrazeneca. They have really stepped up to the mark and I am grateful for each and every one.”
It is Randox’s priority to ensure that we contribute to the global effort to fight COVID-19, by testing at scale. We are therefore absolutely committed to the government testing scheme, which is focusing on key workers and the maintenance of critical national infrastructure – including that of the NHS.
In order to meet the requirements of this scheme, we have undertaken considerable reorganisation within the company by redeploying personnel – often to newly formed departments and newly formed teams. Everyone at Randox has a critical role to play in the practical application of COVID-19 testing and we appreciate all the hard work, patience, and flexibility of our staff.
Our work has greatly expanded the capacity for testing in the UK and we will continue to ramp up our capabilities, to both save lives and promote a timely return to a more normal society.
What we are doing is making a real and positive difference.
For further information please email email@example.com
To watch the full version of the Daily Coronavirus Briefing from 23rd April, please click here.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our Randox Products and Services
Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have the largest test menu of over 100 assays, covering over 100 disease markers including specific proteins, lipids, therapeutic drug monitoring, drugs of abuse, antioxidants, coagulation, diabetes and veterinary testing.
Some of the key benefits of Randox Reagents include:
Randox reagents can help create cost-savings for laboratories through excellent reagent stability; by eliminating the need for costly re-runs through the excellent quality of products. We also offer a range of kit sizes including smaller kit sizes for niche tests to reduce waste.
Reduce the risk of errors and have confidence in patient results
Our traceability of material and extremely tight manufacturing tolerances ensure uniformity across reagent batches reducing lot-to-lot variability. In addition, our assays are validated against gold-standard methods, giving you the confidence that you are sending out the correct patient results.
Reduce your time spent on running tests through liquid ready-to-use reagents, automated methods (compared to the traditional laborious ELISA methods used for some tests such as cystatin C or adiponectin) as well as our easy-fit options.
Expand your routine testing
With speciality assays for 195 of the most common clinical chemistry analysers; assays which usually require dedicated equipment, or was previously only available as an ELISA, can now be run on automated biochemistry analysers, allowing your laboratory to expand its routine test menu. For example, cystatin C, adiponectin, TxBCardio™ and many more.
Bring testing in-house
With smaller kit sizes and excellent reagent stability (most are stable for 28 days on-board the analyser), you don’t have to worry about reagent wastage, allowing testing to be brought in-house rather than sent to external laboratories.
Expand your test menu without expanding your lab
There is no need to buy any extra equipment in order to expand your test menu. Our reagents can be programmed onto the majority of the most common biochemistry analysers. At present, we have hundreds of applications available.
Visit our Reagents Resource Hub and Download our reagents brochure for information on the full range of biochemistry reagents.
Randox reagents are available for a wide range of clinical chemistry analysers. For more information, please contact firstname.lastname@example.org
16 April 2020
Randox unveils whole pathogen molecular controls for SARS-CoV-2 (COVID-19)
Whole pathogen quality controls to support accurate coronavirus testing have been developed by scientists in the UK.
The molecular controls, available from global diagnostics company Randox Laboratories, are currently being used as part of a nationwide testing programme for frontline NHS workers.
Alongside its pioneering COVID-19 tests, performed on its proprietary Biochip, Randox is using these third-party quality controls to ensure accurate coronavirus test and system performance, and ultimately, guarantee laboratory quality assurance.
Lynsey Adams, Randox Quality Control Manager, explained;
“Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control.
“Designed specifically for laboratories currently managing COVID-19 testing, Randox SARS-CoV-2 controls help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples, and importantly, give clinicians absolute confidence in any COVID-19 diagnoses they may make.”
Available under the brand name Qnostics, the new SARS-CoV-2 controls are manufactured using whole pathogens. They therefore mimic the patient sample, providing the best sample matrix for laboratories.
“The Randox Qnostics SARS-CoV-2 controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”
The new coronavirus controls from Randox, which contain the entire SARS-CoV-2 genome, including the conserved regions recommended by CDC and WHO, are compatible for use with both commercial and in-house testing methods, and are quantified by digital PCR to ensure batch to batch reproducibility.
“We are proud to be able to support the high demand for coronavirus testing by delivering a full COVID-19 testing package – not only our COVID-19 tests on the Randox Biochip, but now also the corresponding molecular control material that will ensure the delivery of accurate, and reliable results.
“The World Health Organization (WHO) has been very clear about the importance of testing in the global efforts to contain and delay COVID-19 and we are pleased that our new controls comply with guidelines not only from the WHO but also from the Centres for Disease Control and Prevention.”
Randox Qnostics SARS-CoV-2 Controls are heat-inactivated to be non-infectious and are manufactured to ISO 13485 standards.
Key Features and Benefits of Randox SARS-CoV-2 Qnostics Controls:
- Whole pathogen controls – the controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays, and target the CDC and WHO consensus sequences
- Monitor the entire testing process – whole pathogen controls are the ideal clinically relevant material for full-process validation, from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
- Non-infectious – the controls are heat-inactivated and gamma-irradiation enabling safe handling of material.
- Highly characterised – the controls are quantified by digital PCR to ensure batch to batch reproducibility.
- Clinically relevant – performance data is available to support the clinical relevance and the compatibility with molecular assays currently in use in clinical laboratories.
- High Quality – the controls are manufactured under ISO 13485 guidelines and are therefore suitable for a broad range of usage.
- Liquid for Ease-of-Use – the controls are conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
- Negative controls available – delivering a complete testing package.
For more information visit www.randox.com/coronavirus-randox
OFFICIAL STATEMENT FROM RANDOX
On the emergence of the Covid-19 threat Randox utilised their years of regulated diagnostic experience to quickly develop and robustly validate a test for the Covid-19 virus. Randox had significant confidence in this test and presented them to Public Health England (PHE) for evaluation. PHE were managing this validation process for each of England, Wales, Scotland and Northern Ireland.
The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test. When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.
We understand that the national plan for the testing of key workers is exactly that, a national plan, inclusive of Northern Ireland. Initially relatively small numbers of tests were sent to the areas of significant national threat in London.
The planning for the national distribution of test kits is being managed by the various relevant statutory agencies however Randox has made the case that tests should be made available locally. Following that engagement, tests have now been made directly available within Northern Ireland and Randox will continue to support Northern Ireland within the UK national plan.
Randox have acted with speed and initiative throughout this crisis and will continue to ramp up our testing capability to support the national testing plan for key workers in Northern Ireland.
Every part of Randox’s business is focused on doing everything we can to support the Covid-19 testing programme, to both save lives and ensure the speediest possible return to a more normal society.
For more information please contact the Randox PR team by emailing email@example.com
- June 2022
- May 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- July 2014
- June 2014